Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib
Nicole Bouché, Miriam Al-Saedy, Eingun James Song
Abstract
Cutaneous lupus erythematosus (CLE) is an autoimmune disorder involving a broad range of dermatologic manifestations that can occur in the presence or absence of associated systemic lupus erythematosus (SLE).1 Subacute cutaneous lupus erythematosus (SCLE) is one of 3 main subtypes of CLE that are differentiated according to histopathology and clinical findings and can be triggered by endogenous or exogenous factors.2 Treatment for SCLE traditionally involved a combination of preventive strategies, topical therapies (such as corticosteroids or calcineurin inhibitors), and systemic therapies for widespread disease, including oral antimalarials, systemic corticosteroids, immunosuppressants, and biologic therapies.